Resources
11 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/9/2021 (updated 4/10/2024)
Background: Racial/ethnic disparities in the use of opioids to treat pain disorders have been previously reported in the emergency department (ED). Further research is needed to better evaluate the impact race/ethnicity may have on the use of opioids in adolescents for the management of pain disorders in the ED.
Posted 9/22/2021 (updated 4/3/2024)
Opioid overdose deaths continue to increase in the United States, reaching 49 860 in 2019, the highest ever recorded.1 Non-Hispanic White individuals were disproportionately affected in the wave of prescription opioid deaths at the turn of the century; however, recent increases driven by heroin and fentanyl have been greater for non-Hispanic Black and Hispanic individuals.
Objectives. To examine trends in opioid overdose deaths by race/ethnicity from 2018 to 2019 across 67 HEALing Communities Study (HCS) communities in Kentucky, New York, Massachusetts, and Ohio.
Posted 7/7/2021 (updated 4/2/2024)
Background: Injecting drug users (IDUs) are at increased risk of acquiring and transmitting HIV and other bloodborne pathogens through the multi-person use of syringes. Although research has shown that increased access to syringes through syringe exchange programs (SEPs) is an effective strategy to reduce risky injection practices many areas of the United States still do not have SEPs. In the absence of SEPs, legislation allowing pharmacies over-the-counter sales of syringes has also been shown to reduce syringe sharing. The success of pharmacy sales however is limited by other legal stipulations, such as drug paraphernalia laws, which in turn may contribute to fear among IDUs about being caught purchasing and carrying syringes.
Posted 2/10/2020 (updated 3/28/2024)
Through enhanced primary care, the Transitions Clinic Network (TCN) seeks to improve the health of people with chronic conditions who return to their
communities from prison.
Posted 6/16/2020 (updated 3/28/2024)
This cross-sectional study included all counties and county-equivalent divisions in the US in 2016. Data on racial/ethnic population distribution were derived from the American Community Survey, and data on locations of facilities providing methadone and buprenorphine were obtained from Substance Abuse and Mental Health Services Administration databases.
Posted 5/18/2020 (updated 3/28/2024)
Overreliance on opioid medications is emblematic of a health care system that incentivizes quick, simplistic answers to complex physical and mental health needs.
Posted 11/1/2022 (updated 3/27/2024)
Racial/ethnic minorities have experienced disproportionate opioid-related overdose death rates in recent years. In this context, inequities were examined in community-based naloxone access across racial/ethnic groups in Massachusetts.
Posted 7/25/2022 (updated 3/27/2024)
Drug overdose deaths increased 30% in the United States from 2019 to 2020. Known health disparities exist in overdose mortality rates, particularly among certain racial/ethnic minority populations. Implementation of an evidence-based, culturally responsive, multi-sectoral approach is critical to reducing disparities in overdose rates. This includes addressing structural barriers and enhancing efforts such as linkage to care and harm reduction services.
Posted 5/11/2022 (updated 3/27/2024)
The rate of drug overdose deaths in the USA has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance-related mortality. This study will address this gap.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.